Šalis: Malta
kalba: anglų
Šaltinis: Medicines Authority
RIFAMPICIN
Sanofi S.R.L Viale L. Bodio, 37/b 20158, Milan, Italy
J04AB02
RIFAMPICIN 600 mg
POWDER AND SOLVENT FOR SOLUTION FOR INFUSION
RIFAMPICIN 600 mg
POM
ANTIMYCOBACTERIALS
Withdrawn
2006-12-29
RIFADIN ® INTRAVENOUS 600MG POWDER AND SOLVENT FOR CONCENTRATE FOR SOLUTION FOR INFUSION _Rifampicin _ IS THIS LEAFLET HARD TO SEE OR READ? PHONE 01 403 5600 FOR HELP. Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. - If any side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Rifadin is and what it is used for 2. Before you take Rifadin 3. How to take Rifadin 4. Possible side effects 5. How to store Rifadin 6. Further information 1. WHAT RIFADIN IS AND WHAT 1. WHAT RIFADIN IS AND WHAT IT IS USED FOR IT IS USED FOR Rifadin Intravenous 600mg Powder and Solvent for Concentrate for Solution for Infusion is one of a group of medicines called antibiotics. It is used to treat tuberculosis (also known as TB) and other similar types of infection. 2. BEFORE YOU TAKE RIFADIN 2. BEFORE YOU USE RIFADIN DO NOT TAKE RIFADIN IF: - You are allergic (hypersensitive) to rifampicin or any of the other ingredients. - You have yellowing of the skin and eyes (jaundice). - You are taking saquinavir or ritonavir for HIV infection (see ‘Taking other medicines’ section below). Do not use if any of the above apply to you. If you are not sure, talk to your doctor, nurse or pharmacist before having Rifadin. WARNINGS AND PRECAUTIONS INFORM YOUR DOCTOR IMMEDIATELY WHILE TAKING THIS MEDICINE • If your symptoms of tuberculosis return or get worse (see 4. Possible side effects) • if you develop new or sudden worsening of shortness of breath, possibly with a dry cough or fever not responding to antibiotic treatment. These could be symptoms of lung inflammation (interstitial lung disease/pneumonitis) and can lead to serious breathing problems due to collection of Perskaitykite visą dokumentą
1. NAME OF THE MEDICINAL PRODUCT Rifadin Intravenous 600mg Powder and Solvent for Concentrate for Solution for Infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Rifampicin 600 mg. Excipients : Sodium 16mg per vial. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM _ _ Powder and solvent for concentrate for solution for infusion. Red sterile lyophilised powder for reconstitution with accompanying ampoule of sterile solvent for dilution for use as an intravenous infusion. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Rifadin for Infusion is indicated in patients with all forms of tuberculosis who are unable to tolerate oral therapy, e.g, post operative or comatose patients in whom gastro-intestinal absorption is impaired. Rifadin for Infusion is also indicated in patients with life threatening or severe infections due to rifampicin sensitive micro-organisms. In-vitro activity has been established against streptococci, staphylococci, enterococci, pneumococci, and in addition, N.gonorrhoea, Proteus spp., H.influenza, E.coli and other Gram-negative organisms. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Treatment with Rifadin for Infusion should preferably include the concomitant use of other appropriate antibiotics to prevent the emergence of resistant strains of the causative organism. Rifadin for infusion is for intravenous infusion only and must not be administered by intramuscular or subcutaneous route (see 4.4 Special Warnings and Precautions for Use). _Adults:_ a single daily administration of 600mg (8 to 12 mg/kg b.w.) given in an intravenous infusion drip over 2 to 3 hours has been found to be effective and well tolerated for adult patients. Serum concentrations following the dosage regimen are similar to those obtained after 600mg by mouth. Lower doses are recommended for frail and elderly patients. A daily dose of 8mg/kg bodyweight should not be exceeded in patients with impaired liver function. When patients are able to accept oral medication, they should be transferred to Rifa Perskaitykite visą dokumentą